Methods for treating rheumatic diseases using a soluble CTLA4 molecule
AssigneeBristol-Myers Squibb Company
InventorsRobert Cohen, Suzette Carr, David Hagerty, Robert J. Peach, Jean-Claude Becker
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for treating rheumatic disease by administering to a subject, soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.
Claims39
A method for treating a rheumatic disease comprising administering to a subject an effective amount of a soluble CTLA4 mutant molecule that binds a B7 molecule.
A method for treating rheumatic disease comprising administering to a subject an effective amount of a soluble CTLA4 mutant molecule that binds a B7 molecule, wherein the soluble CTLA4 mutant molecule comprises a mutation at position +104 of CTLA4, wherein leucine at position +104 as shown in FIG. 23 is substituted with glutamic acid and a mutation at position +29 of CTLA4, wherein alanine at position +29 as shown in FIG. 23 is substituted with tyrosine.
A pharmaceutical composition for treating a rheumatic disease comprising a pharmaceutically acceptable carrier and a soluble CTLA4 mutant molecule.
A kit for treating rheumatoid arthritis, said kit comprising an effective amount of a soluble CTLA4 mutant molecule that binds to a B7 molecule.
Dependencies are inferred from the claim text.